Menopause Symptom Score (MRS)

Professionals in health and medical use Menopause Symptoms as part of their standard analytical workflow to verify calculations, reduce arithmetic errors, and produce consistent results that can be documented, audited, and shared with colleagues, clients, or regulatory bodies for compliance purposes.

University professors and instructors incorporate Menopause Symptoms into course materials, homework assignments, and exam preparation resources, allowing students to check manual calculations, build intuition about input-output relationships, and focus on conceptual understanding rather than arithmetic.

Consultants and advisors use Menopause Symptoms to quickly model different scenarios during client meetings, enabling real-time exploration of what-if questions that would otherwise require returning to the office for detailed spreadsheet-based analysis and reporting.

Individual users rely on Menopause Symptoms for personal planning decisions — comparing options, verifying quotes received from service providers, checking third-party calculations, and building confidence that the numbers behind an important decision have been computed correctly and consistently.

What is the difference between perimenopause and menopause?

Perimenopause refers to the transitional period leading up to the final menstrual period (FMP), during which cycles become irregular and menopausal symptoms begin. It typically lasts 4–6 years but can extend longer. Menopause is the point of the FMP itself, confirmed retrospectively after 12 months of amenorrhoea. Postmenopause refers to the years after the FMP. Many women experience the most severe symptoms during perimenopause, not after menopause.

Is HRT safe?

Modern HRT (particularly transdermal oestradiol with micronised progesterone) has a substantially better safety profile than older oral combined HRT. Transdermal oestradiol does not increase VTE (blood clot) risk. Micronised progesterone has a lower breast cancer risk signal than synthetic progestogens. For healthy women under 60 or within 10 years of menopause, the benefits of HRT for symptom control, bone protection, and cardiovascular health typically outweigh risks. Individual risk assessment is essential.

What is the STRAW+10 staging system?

The Stages of Reproductive Aging Workshop (STRAW) system divides the female reproductive lifespan into stages: reproductive (early, peak, late), menopausal transition (early: irregular cycles; late: amenorrhoea ≥60 days), and postmenopause (early: first 6 years; late: remaining years). STRAW+10 (updated 2012) added criteria including hormonal (FSH, AMH) and ultrasound (AFC) parameters to characterise each stage more precisely and improve clinical applicability.

What non-hormonal options are available for menopausal symptoms?

For vasomotor symptoms: SSRIs/SNRIs (paroxetine, venlafaxine, desvenlafaxine), clonidine, gabapentin, and fezolinetant (a neurokinin 3 receptor antagonist, NICE approved 2024) are evidence-based non-hormonal options. For urogenital symptoms: local vaginal oestrogen is highly effective and has minimal systemic absorption. Cognitive behavioural therapy (CBT) has good evidence for hot flushes and mood symptoms. Lifestyle measures (reduced alcohol, weight management, cooling strategies) provide modest benefit.

Does HRT increase breast cancer risk?

Breast cancer risk with HRT depends on the type and duration of treatment. Oestrogen-only HRT (in women without a uterus) does not appear to increase and may slightly reduce breast cancer risk in some studies. Combined oestrogen-progestogen HRT is associated with a small increased risk, particularly after 5 years of use. Micronised progesterone (Utrogestan) has a lower risk signal than synthetic progestogens such as medroxyprogesterone acetate. The absolute risk increase is small — approximately 5 extra cases per 1,000 women over 5 years of use.

What is premature ovarian insufficiency (POI)?

POI is defined as the cessation of ovarian function before the age of 40, occurring in approximately 1% of women. It is diagnosed by elevated FSH (>25 IU/L on two measurements 4–6 weeks apart) combined with amenorrhoea or oligomenorrhoea. POI requires HRT (not contraceptive pills) until the natural age of menopause (approximately 51 years) to prevent premature bone loss and cardiovascular disease. Unlike natural menopause, POI is associated with 5–10% chance of spontaneous ovulation and conception.

Can menopausal symptoms affect work and relationships?

Yes significantly. A 2021 UK Menopause Society survey found that approximately 1 in 10 women leave work due to menopausal symptoms and nearly 1 in 3 report that symptoms negatively impact their work performance. Cognitive symptoms ('brain fog'), fatigue, low mood, and sleep disturbance have the greatest impact on occupational function. Effective treatment substantially improves quality of life, work productivity, and relationship satisfaction.

How long should HRT be taken?

There is no mandated maximum duration for HRT. Duration should be based on individual assessment of symptoms, risks, and benefits reviewed annually. Many women choose to take HRT for 5–10 years or longer for symptom control, bone protection, and quality of life. The NICE menopause guideline (NG23) states that HRT may be continued for as long as the benefits outweigh the risks for the individual woman.